Early Detection of Recurrent Ovarian Cancer in Patients with Low-Level Increases in Serum CA-125 Levels by 2-[F-18]Fluoro-2-Deoxy-D-Glucose-Positron Emission Tomography/Computed Tomography

被引:30
作者
Peng, Nan-Jing [1 ,2 ]
Liou, Wen-Shiung [3 ]
Liu, Ren-Shyan [2 ,4 ]
Hu, Chin [1 ]
Tsay, Daw-Guey [1 ]
Liu, Cheng-Bin [3 ]
机构
[1] Kaohsiung Vet Gen Hosp, Dept Nucl Med, Kaohsiung 813, Taiwan
[2] Natl Yang Ming Univ, Sch Med, Taipei 112, Taiwan
[3] Kaohsiung Vet Gen Hosp, Dept Obstet & Gynecol, Kaohsiung 813, Taiwan
[4] Taipei Vet Gen Hosp, Dept Nucl Med, Taipei, Taiwan
关键词
cancer; FDG; imaging; PET; ONCOLOGIC PET REGISTRY; FOLLOW-UP; F-18-FDG PET/CT; NORMAL RANGE; CA125; NADIR; FDG-PET/CT; CARCINOMA; PROGRESSION; MANAGEMENT; 2-<FLUORINE-18>-FLUORO-2-DEOXY-D-GLUCOSE;
D O I
10.1089/cbr.2010.0872
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Serum CA-125 has been shown to be a sensitive tumor marker of recurrent ovarian cancer. The goal of this study was to evaluate the use of 2-[F-18]fluoro-2-deoxy-d-glucose-positron emission tomography/computed tomography (FDG-PET/CT) in the early detection of recurrent ovarian cancer in patients with low-level increases in serum CA-125 levels. Methods: Patients who demonstrated a normalization of serum CA-125 levels after complete remission of ovarian cancer were recruited for this study. FDG-PET/CT was performed to evaluate serum CA-125 levels >= 35 U/mL (Group 1) or progressive low-level increases in the levels of serum CA-125 (Group 2). The results were analyzed based on pathology, disease progression, and/or clinical follow-up. Results: Twenty-seven (27) consecutive patients consented to the aforementioned criteria (n = 16 in Group 1 and n = 11 in Group 2). In Group 1, of the 16 patients, 15 had a proven tumor recurrence, and the remaining 1 had a second primary cancer with no evidence of recurrent ovarian lesions. In Group 2, all 11 patients had recurrent tumors. The use of FDG-PET/CT allowed the detection of recurrences in 25 patients and a second primary cancer in 1 patient, which included all of the patients in Group 1 and 10 of the 11 patients in Group 2. The detection rate of FDG-PET/CT for recurrent ovarian cancer was 100% in Group 1 and 90.9% in Group 2 (15/15 vs. 10/11, p = 0.423). FDG-PET/CT changed the intended management in 14 (53.8%) of the patients, which included 4 cases in Group 1 and 10 cases in Group 2. Conclusions: FDG-PET/CT has the ability to detect recurrent ovarian cancer and second primary tumors in patients with increased levels of serum CA-125. FDG-PET/CT affects the clinical management by localizing recurrent lesions and creating a specific treatment plan for each patient, especially patients who demonstrate a low-level increase in serum CA-125 levels.
引用
收藏
页码:175 / 181
页数:7
相关论文
共 28 条
  • [1] Clinically occult recurrent ovarian cancer: patient selection for secondary cytoreductive surgery using combined PET/CT
    Bristow, RE
    del Carmen, MG
    Pannu, HK
    Cohade, C
    Zahurak, ML
    Fishman, EK
    Wahl, RL
    Montz, FJ
    [J]. GYNECOLOGIC ONCOLOGY, 2003, 90 (03) : 519 - 528
  • [2] Chang WC, 2002, NEOPLASMA, V49, P329
  • [3] Synchronous primary cancers of the endometrium and ovary
    Chiang, Y. -C.
    Chen, C. -A.
    Huang, C. -Y.
    Hsieh, C. -Y.
    Cheng, W. -F.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2008, 18 (01) : 159 - 164
  • [4] Crawford SM, 2004, J CLIN ONCOL, V22, p449S
  • [5] De Rosa V., 1995, European Journal of Gynaecological Oncology, V16, P123
  • [6] Diagnostic accuracy of FDG PET in the follow-up of platinum-sensitive epithelial ovarian carcinoma
    Garcia-Velloso, Maria Jose
    Jurado, Matias
    Ceamanos, Carolina
    Manuel Aramendia, Jose
    Puy Garrastachu, Maria
    Lopez-Garcia, Guillermo
    Angel Richter, Jose
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2007, 34 (09) : 1396 - 1405
  • [7] CA 125, PET alone, PET-CT, CT and MRI in diagnosing recurrent ovarian carcinoma A systematic review and meta-analysis
    Gu, Ping
    Pan, Ling-Ling
    Wu, Shu-Qi
    Sun, Li
    Huang, Gang
    [J]. EUROPEAN JOURNAL OF RADIOLOGY, 2009, 71 (01) : 164 - 174
  • [8] Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: Initial results from the national oncologic PET registry
    Hillner, Bruce E.
    Siegel, Barry A.
    Liu, Dawei
    Shields, Anthony F.
    Gareen, Ilana F.
    Hanna, Lucy
    Stine, Sharon Hartson
    Coleman, R. Edward
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (13) : 2155 - 2161
  • [9] Relationship Between Cancer Type and Impact of PET and PET/CT on Intended Management: Findings of the National Oncologic PET Registry
    Hillner, Bruce E.
    Siegel, Barry A.
    Shields, Anthony F.
    Liu, Dawei
    Gareen, Ilana F.
    Hunt, Ed
    Coleman, R. Edward
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2008, 49 (12) : 1928 - 1935
  • [10] 18F-FDG PET/CT evaluation of patients with ovarian carcinoma
    Iagaru, Andrei H.
    Mittra, Erik S.
    McDougall, Iain Ross
    Quon, Andrew
    Gambhir, Sanjiv Sam
    [J]. NUCLEAR MEDICINE COMMUNICATIONS, 2008, 29 (12) : 1046 - 1051